United Kingdom (UK)
Recombinant monoclonal antibody to Influenza A HA. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the EBV transformed human B cell clone HA.
Alternative Name(s) of Target: hemagglutinin; haemagglutinin
Immunogen: Made by immortalizing IgG-expressing B cells from individuals following vaccination with seasonal influenza vaccine, containing H1 and H3 influenza Virus subtypes.
Specificity: This antibody specifically recognizes the conformational epitope in the stem region of HA in which amino acid sequences are highly conserved in H1N1, H5N1, H6N1, and H9N2 subtypes of Influenza A viru This antibody uses the VH1-69*01, D3-10*01, JH5*02, VL2D-29*02 and JL4. This antibody does not cross react with HA in H2N2, H3N2 and H7N7 subtype of Influenza A Virus. This antibody has no effect on haemagglutination-inhibition activity.
Antibody first published in:
Corti, D. et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest 120, 1663–1673 (2010). PMID:20389023
Note on publication:
Describes the isolation and analysis of a panel of human antibodies from vaccinated individuals and its evaluation using Virus neutralization assays.
ELISA using HA (Ab00151) and Influenza A HA [A/Hong Kong/483/97 (H5N1)]. Binding curves of the mouse IgG chimeric version of the Anti-Influenza A HA antibody HA (Ab00151-1.1; green line) and isotype control (Ab00102-1.1, anti-fluorescein; orange line) to an ELISA plate coated with Influenza A HA [A/Hong Kong/483/97 (H5N1)] at a concentration of 2.5 ug/ml. A 3-fold serial dilution from 3000 to 0.0169 ng/ml was performed using Ab00151 antibody. For signal detection, a 1:4000 dilution of a HRP-conjugated anti-mouse IgG antibody was used.